For most of its life, Arrowhead Pharmaceuticals was a company that spent money and promised science. It had no approved drug until November 2025, when the FDA cleared REDEMPLO (plozasiran) for a rare fat-metabolism disorder. Then, in the span of about nine months, the story changed shape almost completely: a second approval in Europe, two positive Phase 3 trials in a much larger patient population, and a string of early-stage results that suggest the pipeline behind the lead drug is genuinely deep. The stock has more than doubled over the past year. The question the latest filing forces is whether the math underneath that move holds together.
In one breath
Arrowhead’s 10-Q for the quarter ended June 30, 2026 shows a company burning roughly $200 million in a single quarter while sitting on $1.6 billion in total liquid resources. The stock trades at a multiple that assumes the pipeline keeps delivering. The open question is whether the cash lasts long enough for the next wave of approvals to arrive, and the filing cannot answer that yet.
What the filing actually says
Two numbers sit side by side in the June 30 filing and they do not look comfortable together. Quarterly revenue was roughly $75 million. R&D expenses for the same period were approximately $198 million, meaning Arrowhead spent about two and a half dollars on research for every dollar it brought in. A household running that ratio would be spending $2,600 a month while earning $1,000. The net loss for the quarter ran well above the revenue line.
The cash position softens that picture somewhat. Total liquid resources, counting cash, restricted cash, and short-term securities, stood at approximately $1.6 billion as of June 30. At the current quarterly burn rate, that is roughly two years of runway, though the pace of spending will shift as commercial operations for REDEMPLO scale up. The filing does not give a forward cash-use projection, so the data cannot answer exactly how long the buffer lasts.
What changed since the prior filing
The prior quarterly filing, for the period ended March 31, 2026, preceded three events that materially changed the company’s position. First, on June 22, 2026, the European Commission granted marketing authorization for REDEMPLO in familial chylomicronemia syndrome, making it the first RNA-interference medicine approved in the EU for that condition. That opens a second commercial geography without requiring another full approval trial.
Second, in July 2026, Arrowhead reported Phase 3 results from its SHASTA-3 and SHASTA-4 studies of plozasiran in severe hypertriglyceridemia, a condition affecting far more patients than the rare disorder the drug was first approved for. Triglyceride reductions were large enough to be clinically meaningful, but the more consequential finding may be the sharp drop in acute pancreatitis events, because pancreatitis hospitalizations are what drive real-world prescribing decisions. On August 4, 2026, Arrowhead acquired a U.S. FDA Priority Review Voucher, which it intends to use for a supplemental drug application in severe hypertriglyceridemia before year-end. A priority review shortens the FDA’s standard review clock by roughly six months, meaning a potential approval could arrive faster than the base case.
Third, on September 15, 2026, interim data from a Phase 1/2a study of ARO-DIMER-PA showed large single-dose reductions in two fat-regulating proteins simultaneously. This is Arrowhead’s first dual-target RNA-interference compound, meaning one injection silences two genes at once. The data are early and from a small study, so they establish direction rather than proof, but the direction is the same as the rest of the pipeline.
What the pipeline compounds
The word “compounds” does double duty here. The pipeline is literally a list of chemical compounds. It also compounds risk and potential in the financial sense, because each program either adds to the case for the platform or subtracts from it.
Beyond plozasiran, the filed pipeline includes fazirsiran in Phase 3 for a genetic lung disease called alpha-1 antitrypsin deficiency, olpasiran in clinical development for elevated lipoprotein(a) (a cardiovascular risk factor with no approved treatment) partnered with Amgen, and ARO-RAGE in Phase 2a for mild asthma. The Phase 3 YOSEMITE study for zodasiran in a severe inherited cholesterol disorder is fully enrolled, with data expected in Q3 2027. On May 5, 2026, Arrowhead licensed ARO-PNPLA3 to Madrigal Pharmaceuticals for a liver-fat disease, receiving $25 million upfront. That deal does two things: it brings in cash and it signals that a larger commercial-stage company sees value in Arrowhead’s technology.
Goldman Sachs, which reinstated coverage on September 24, 2026, with a Neutral rating and an analyst valuation estimate well below the thirteen-analyst consensus, cited current unprofitability. Citi and HC Wainwright, both as of early September 2026, set analyst valuation estimates meaningfully above that consensus, reflecting confidence in the pipeline cadence. Those are their views, attributed to them; BullScope’s framework observes only that the gap between the most cautious and most optimistic estimates is itself a measure of how much disagreement the data have not yet resolved.
What the filing cannot tell us
The June 30 filing predates the September 15 ARO-DIMER-PA data and the Goldman reinstatement. It also cannot tell us how REDEMPLO’s commercial launch is tracking in units sold, because the revenue line mixes collaboration payments with product sales without a clean split available in the dossier. The supplemental drug application for severe hypertriglyceridemia has not yet been filed as of this writing, so the FDA’s response, and the timeline it implies, remains open. Those are the three things that will define the next chapter, and none of them are in the current filing.
Reading the numbers
- $1.6 billion in total liquid resources (June 30, 2026). This is cash, short-term securities, and restricted cash combined, as filed in the June 30, 2026 10-Q. Think of it as the fuel tank. At roughly $200 million burned per quarter, the tank holds about eight quarters’ worth of fuel at the current rate, though commercial revenue will change that math as REDEMPLO scales. A household analogy: a family with $160,000 in savings spending $20,000 a quarter has two years before the account hits zero, assuming no new income.
- $198 million in R&D expense, one quarter. Filed in the same 10-Q. That is more than Arrowhead’s entire annual revenue as recently as fiscal year 2021, per the company’s fiscal year 2021 10-K filed with the SEC. The number signals a company in full acceleration, not consolidation. Whether the pipeline justifies that rate is the central question the data cannot yet close.
- 79% and 81% median triglyceride reductions (SHASTA-3 and SHASTA-4). Reported in July 2026. Triglycerides are fats in the blood; very high levels can trigger pancreatitis, a painful and dangerous inflammation of the pancreas. A reduction of roughly 80% in a Phase 3 trial is clinically large. The accompanying 78% drop in pancreatitis events is what turns a lab number into a reason a doctor writes a prescription.
- P/S ratio of 12.2 versus a decade median of 20.0, calculated by BullScope using price and revenue data from SEC filings and S&P Global Market Intelligence; see our valuation methodology at bullscope.ai/methodology. A price-to-sales ratio is the price tag the market puts on each dollar of annual revenue. At 12.2, Arrowhead trades at the 12th percentile of its own history, meaning the market is paying less relative to sales than it has for 88% of the past decade, based on the same dataset and methodology. That sounds cheap until one notes that FY2024 revenue was $4 million and FY2025 was $829 million, per our data from the fiscal year 2025 10-K. The revenue base is so new and so volatile that the ratio is more a marker of uncertainty than of value.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended September 30, 2025 (SEC EDGAR)
- Arrowhead Q3 2026 earnings call transcript (Seeking Alpha)
- Arrowhead plans sNDA by end of 2026 (Seeking Alpha)
- Arrowhead 10-K report (TradingView)
- Goldman Sachs resumes coverage (TradingView)
- European Commission approval (The Pharma Letter)
- ARO-DIMER-PA data and plozasiran launch update (MarketBeat)
